We’re thrilled to announce the acceptance of three abstracts, including a poster of distinction, at the American Association for the Study of Liver Diseases @AASLDtweets annual conference: The Liver Meeting #TLM25 Read more: https://t.co/3Uvm2FjhVE Check out the abstracts:

Check out our new look ✨ We’re developing targeted therapies across a broad array of diseases and tissue types. The science is unparalleled, our team is in a strong position to realize the mission, and we’re excited to share more about our work. On our new website, you can

Jenny Marlowe and Melissa Bonner of @nchromabio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies. https://t.co/RY4hFt977h

nChroma Bio is attending #TIDESUSA: Oligonucleotide & Peptide Therapeutics! Tomorrow, nChroma CSO Melissa Bonner, joins John Zuris, Manmohan Singh, Tyler Goodwin, and Priya Karmali to discuss bringing advanced modalities in the gene and cell therapy space into the clinic and

@nchromabio is headed to #ASGCT2025 next month! We’re excited to share the acceptance of three abstracts, one for oral presentation and two for poster presentations, at the @ASGCTherapy annual conference. For details on where you can find the team and their abstracts, visit:

We’re thrilled to announce the launch of nChroma Bio today, formed through the strategic merger of @chromamedicine and @nvelop_tx , to pioneer a new class of genetic medicines. Read more: https://t.co/D3xMxkNUfx